38 completed, 6 not yet recruiting, 5 unknown, 4 terminated. 56 Phase 3, 13 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 56 | Completed 38, Not yet recruiting 6, Unknown 5, Terminated 4, Recruiting 2, Active not recruiting 1 |
| Phase 2 | 13 | Completed 8, Not yet recruiting 2, Terminated 2, Unknown 1 |
Follow Helminthiasis: new trials by email Literature Review of Helminthiasis trials Research Report on Helminthiasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oxfendazole in Mild Parenchymal Brain Cysticercosis Oxfendazole single dose, Oxfendazole three doses, albendazole plus praziquantel regime - Brain Cysticercosis | Phase 2 / Phase 3 | Not yet recruiting | Universidad Peruana Cayetano Heredia | 544 | 2026-12-01 | 2026-05-01 |
| Efficacy and Safety of Emodepside in Participants With Soil-transmitted Helminth Infections emodepside (BAY 44-4400), Mebendazole 100 MG, similar placebo to mebendazole - Trichuris Trichiura; Infection, Hookworm Infection | Phase 3 | Not yet recruiting | Swiss Tropical & Public Health Institute | 315 | 2026-11-06 | 2026-08-14 |
| Different Treatment Frequencies for Hepatic Fibrosis Due to Schistosomiasis Praziquantel 40 mg/kg per dose given once annually, Praziquantel 40 mg/kg given three times per year - Schistosomiasis, Schistosoma Mansoni | Phase 2 / Phase 3 | Not yet recruiting | Rhode Island Hospital | 600 | 2026-11-01 | 2026-08-12 |
| Combination Therapies for Trichuris Trichiura Infection in Schoolchildren in Honduras Placebo, Albendazole 400 mg, Albendazole Plus Ivermectin - Trichuriasis, Strongyloidiasis | Phase 3 | Not yet recruiting | Mundo Sano Foundation | 368 | 2026-11-01 | 2026-06-23 |
| Follow-up Assessment of Change in Soil-transmitted Helminths Infection Intensity in Uganda Albendazole 400mg, Ivermectin 3 mg - Ascariasis | Phase 3 | Not yet recruiting | Jennifer Keiser | 450 | 2026-10-01 | 2026-10-14 |
| Better Options for Lymphatic Filariasis Treatment MoxDA - Moxidectin + Diethylcarbamzine (DEC) + Albendazole, IDA - Ivermectin + DEC + albendazole - Lymphatic Filariasis, Scabies | Phase 3 | Recruiting | Medicines Development for Global Health | 5100 | 2026-09-28 | 2026-10-07 |
| Efficacy and Safety of Emodepside in Participants With Soil-transmitted Helminth Infections emodepside (BAY 44-4400), matching placebo of emodepside, Mebendazole - Trichuris Trichiura; Infection, Hookworm Infection | Phase 3 | Completed | Swiss Tropical & Public Health Institute | 315 | 2025-11-25 | 2026-10-08 |
| Real World Evaluation of an Albendazole-Ivermectin Coformulation Safety and Effectiveness Pre-screening Phase, Screenig Phase, Randomization - Soil-Transmitted Helminths | Phase 3 | Recruiting | Insud Pharma | 20000 | 2025-09-01 | 2025-09-15 |
| 21-day Double-blind Trial of Albendazole in Adults With Loa Loa Microfilaremia Albendazole 400mg, Placebo - Loiasis With Positive Blood Microfilaremia, Loiasis | Phase 3 | Not yet recruiting | Programme National de Lutte contre l'Onchocercose, Republic of the Congo | 100 | 2025-01-15 | 2024-09-26 |
| A 3- to 5-day Clinical Trial of Levamisole in Loiasis Infected Subjects Levamisole 3 days, Levamisole 5 days, Placebo - Loiasis | Phase 2 / Phase 3 | Unknown | Programme National de Lutte contre l'Onchocercose, Republic of the Congo | 99 | 2024-06-21 | 2024-09-20 |
| Efficacy and Safety of Moxidectin-Albendazole Co-administration in SAC Moxidectin 2 mg Oral Tablet, Albendazole 400 mg Oral Tablet, Placebo Moxidectin - Trichuriasis, Ascariasis | Phase 3 | Completed | Jennifer Keiser | 224 | 2024-05-14 | 2025-09-19 |
| Efficacy of Ivermectin-albendazole vs Albendazole Alone in School-aged Children Infected With Trichuris Trichiura IVM (200 µg/kg) + ALB (400 mg), ALB (400mg) - Trichuriasis | Phase 3 | Completed | Jennifer Keiser | 161 | 2023-10-09 | 2024-04-10 |
| Evaluation of Effectiveness of ALBENDAZOLIVERMECTIN Coformulation vs ALBENDAZOLE for Treatment of Intestinal Worms Albendazole and Ivermectin fixed dose coformulation, Albendazole - Helminthes; Infestation, Intestinal | Phase 2 / Phase 3 | Terminated | Barcelona Institute for Global Health | 1001 | 2022-01-20 | 2025-09-22 |
| Efficacy and Safety of MOX/ALB Co-administration Moxidectin 2 mg Oral Tablet, Albendazole 400 mg Oral Tablet, Ivermectin 3 mg Oral Tablet - Trichuriasis, Ascariasis | Phase 3 | Completed | Jennifer Keiser | 255 | 2021-06-15 | 2024-01-24 |
| Clinical Evaluation of Ujiplus® Against Schistosoma Mansoni Ujiplus®, Praziquantel 400mg - Schistosoma Mansoni | Phase 2 / Phase 3 | Completed | Kenya Medical Research Institute | 400 | 2021-05-06 | 2022-07-12 |
| Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Onchocerciasis Moxidectin, Ivermectin - Onchocerciasis | Phase 3 | Active not recruiting | Medicines Development for Global Health | 323 | 2021-05-03 | 2025-12-23 |
| Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole Moxidectin, Ivermectin, Albendazole - Onchocerciasis | Phase 3 | Completed | Medicines Development for Global Health | 12979 | 2021-05-03 | 2026-03-03 |
| Adjunctive Ivermectin Mass Drug Administration for Malaria Control Ivermectin, Placebo, Dihydroartemisinin-piperaquine - Malaria,Falciparum, Neglected Tropical Diseases | Phase 3 | Unknown | London School of Hygiene and Tropical Medicine | 24000 | 2021-05-03 | 2022-02-24 |
| Efficacy and Safety of MOX/ALB vs. IVM/ALB Co-administration moxidectin (8 mg) / albendazole (400 mg), ivermectin (200 µg/kg) / albendazole (400 mg), ALBENDAZOLE 400 Mg ORAL TABLET [ZENTEL] - Trichuriasis, Ascariasis | Phase 2 / Phase 3 | Completed | Jennifer Keiser | 536 | 2021-03-01 | 2024-12-05 |
| Moxidectin for LF, Cote d'Ivoire (DOLF) Ivermectin, Diethylcarbamazine, Albendazole - Lymphatic Filariasis | Phase 3 | Completed | Washington University School of Medicine | 164 | 2020-08-20 | 2026-01-29 |
Showing 20 of 56. Sign in to see all of them.
Schistosomiasis (10) · Elephantiasis, Filarial (8) · Trichuriasis (8) · Ancylostomiasis (7) · Hookworm Infections (7) · Neurocysticercosis (7) · Onchocerciasis (7) · Strongyloidiasis (7) · Filariasis (6) · Schistosomiasis haematobia (6) · Ascariasis (5) · Lymphedema (3) · Malaria (3) · Scabies (3)
Infections (56) · Parasitic Diseases (56) · Nematode Infections (31) · Secernentea Infections (29) · Vector Borne Diseases (23) · Spirurida Infections (16) · Trematode Infections (14) · Skin Diseases (11) · Skin Diseases, Infectious (11) · Skin and Connective Tissue Diseases (11) · Filariasis (10) · Hemic and Lymphatic Diseases (10) · Skin Diseases, Parasitic (10) · Mosquito-Borne Diseases (9)
Albendazole (27) · Ivermectin (18) · Praziquantel (14) · moxidectin (7) · Doxycycline (3) · Mebendazole (3) · Tablets (3) · Albumins (2) · Bay 44-4400 (2) · Dexamethasone (2) · Diethylcarbamazine (2) · Intravital Microscopy (2) · emodepside (2) · Acetazolamide (1) · Artesunate (1)
Jennifer Keiser (6) · Medicines Development for Global Health (4) · Universidad Peruana Cayetano Heredia (4) · Kenya Medical Research Institute (3) · The Task Force for Global Health (3) · Programme National de Lutte contre l'Onchocercose, Republic of the Congo (2) · Swiss Tropical & Public Health Institute (2) · University Hospitals Cleveland Medical Center (2) · Albert Einstein College of Medicine (1) · All India Institute of Medical Sciences (1) · Barcelona Institute for Global Health (1) · Centre de Recherche Médicale de Lambaréné (1) · Centro per le Malattie Tropicali (1) · Colorado State University (1) · Columbia University (1)
Côte d’Ivoire (6) · Kenya (5) · Tanzania (5) · Ghana (4) · India (4) · Peru (4) · Democratic Republic of the Congo (3) · Uganda (3) · Ethiopia (2) · Mali (2) · Republic of the Congo (2) · Senegal (2) · Sri Lanka (2) · United States (2) · Argentina (1)
Eric Ottesen, MD (3) · Benjamin Koudou, PhD (2) · Elijah M Songok, PhD (2) · Hector H. Garcia, MD, PhD (2) · Jennifer Keiser, Professor (2) · Tony Ukety, MD, DO, MPH (2) · Alejandro Javier Krolewiecki, PhD, MD (1) · Alejandro Krolewiecki, MD (1) · Andrea Kreidenweiss, PhD (1) · Anna R Last, MBChB PhD (1) · Ayat A Haggag, MD (1) · Bodo S Randrianasolo, MD (1)
PMID 11873261, PMID 22610930, PMID 32228663, PMID 10656038, PMID 18414647, PMID 18495737, PMID 19802383, PMID 20705516, PMID 21332573, PMID 21572981, PMID 21729382, PMID 24063608, PMID 24999157, PMID 26984901, PMID 29346377, PMID 29361335, PMID 30526582, PMID 30532268, PMID 30878222, PMID 30885157, PMID 30969960, PMID 31558376, PMID 32196506, PMID 32993559, PMID 33137100, PMID 33930024, PMID 33979325, PMID 34168029, PMID 34191812, PMID 34226233, PMID 34281614, PMID 34403424, PMID 34632308, PMID 34856181, PMID 35217670, PMID 35476631, PMID 35701056, PMID 35788749, PMID 35803632, PMID 36342912, PMID 36354034, PMID 36461087, PMID 36540062, PMID 36548444, PMID 36893784, PMID 36897877, PMID 36917597, PMID 37036890, PMID 37357904, PMID 37419638
2008 (1), 2016 (1), R01AI155739 (1), R01AI184979 (1), R01NS054805 (1)